Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,809 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The tumor immune microenvironment and therapeutic efficacy of trastuzumab deruxtecan in gastric cancer.
Koganemaru S, Koyama S, Suto F, Koga M, Inaki K, Kuwahara Y, Arita T, Hirata T, Goto H, Wada N, Kobayashi M, Shibutani T, Okabayashi T, Nakamaru K, Kawazoe A, Togashi Y, Nishikawa H, Shitara K. Koganemaru S, et al. Among authors: koga m. Cancer Res Commun. 2024 Dec 16. doi: 10.1158/2767-9764.CRC-24-0302. Online ahead of print. Cancer Res Commun. 2024. PMID: 39679910 Free article.
HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01.
Siena S, Raghav K, Masuishi T, Yamaguchi K, Nishina T, Elez E, Rodriguez J, Chau I, Di Bartolomeo M, Kawakami H, Suto F, Koga M, Inaki K, Kuwahara Y, Takehara I, Barrios D, Kobayashi K, Grothey A, Yoshino T. Siena S, et al. Among authors: koga m. Nat Commun. 2024 Nov 25;15(1):10213. doi: 10.1038/s41467-024-53223-3. Nat Commun. 2024. PMID: 39587050 Free PMC article. Clinical Trial.
Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial.
Raghav K, Siena S, Takashima A, Kato T, Van den Eynde M, Pietrantonio F, Komatsu Y, Kawakami H, Peeters M, Andre T, Lonardi S, Yamaguchi K, Tie J, Castro CG, Hsu HC, Strickler JH, Kim TY, Cha Y, Barrios D, Yan Q, Kamio T, Kobayashi K, Boran A, Koga M, Allard JD, Yoshino T. Raghav K, et al. Among authors: koga m. Lancet Oncol. 2024 Sep;25(9):1147-1162. doi: 10.1016/S1470-2045(24)00380-2. Epub 2024 Aug 5. Lancet Oncol. 2024. PMID: 39116902 Clinical Trial.
Wound, Pressure Ulcer, and Burn Guidelines-5: Guidelines for the management of lower leg ulcers and varicose veins, second edition.
Ito T, Kukino R, Sarayama Y, Tanioka M, Maekawa T, Yatsushiro H, Asai J, Asano Y, Abe M, Amano M, Ikegami R, Ishii T, Isei T, Isogai Z, Inoue Y, Irisawa R, Iwata Y, Otsuka M, Omoto Y, Kato H, Tanizaki H, Kadono T, Kaneko S, Kanoh H, Kawakami T, Kawaguchi M, Kono T, Koga M, Kodera M, Sakai K, Sakurai E, Shintani Y, Tsujita J, Doi N, Nakanishi T, Hashimoto A, Hasegawa M, Hayashi M, Hirosaki K, Fujita H, Fujimoto M, Fujiwara H, Matsuo K, Madokoro N, Motegi SI, Yamasaki O, Yoshino Y, Le Pavoux A, Tachibana T, Ihn H. Ito T, et al. Among authors: koga m. J Dermatol. 2024 Dec 26. doi: 10.1111/1346-8138.17503. Online ahead of print. J Dermatol. 2024. PMID: 39723550
Atherogenic Dyslipidemia Is Critically Related to Aortic Complicated Lesions in Cryptogenic Stroke.
Kikuno M, Ueno Y, Tateishi Y, Kuriki A, Doijiri R, Shimizu T, Takekawa H, Kanemaru K, Shimada Y, Yamaguchi E, Koga M, Kamiya Y, Ihara M, Tsujino A, Hirata K, Hasegawa Y, Aizawa H, Terashi H, Hattori N, Urabe T; CHALLENGE ESUS/CS collaborators. Kikuno M, et al. Among authors: koga m. J Atheroscler Thromb. 2024 Dec 26. doi: 10.5551/jat.65289. Online ahead of print. J Atheroscler Thromb. 2024. PMID: 39721702 Free article.
Long-term changes in carotid intima-media thickness according to baseline blood pressure level: J-STARS Echo study.
Wada S, Koga M, Kagimura T, Toyoda K, Nagai Y, Aoki S, Nezu T, Hosomi N, Origasa H, Ohtsuki T, Maruyama H, Yasaka M, Kitagawa K, Uchiyama S, Minematsu K, Matsumoto M; Japan Statin Treatment Against Recurrent Stroke (J-STARS) Echo Study Collaborators. Wada S, et al. Among authors: koga m. J Neurol Sci. 2024 Dec 9;468:123342. doi: 10.1016/j.jns.2024.123342. Online ahead of print. J Neurol Sci. 2024. PMID: 39673820
Dysbiosis of gut microbiota in COVID-19 is associated with intestinal DNA phage dynamics of lysogenic and lytic infection.
Ishizaka A, Tamura A, Koga M, Mizutani T, Yamayoshi S, Iwatsuki-Horimoto K, Yasuhara A, Yamamoto S, Nagai H, Adachi E, Suzuki Y, Kawaoka Y, Yotsuyanagi H. Ishizaka A, et al. Among authors: koga m. Microbiol Spectr. 2024 Dec 10:e0099824. doi: 10.1128/spectrum.00998-24. Online ahead of print. Microbiol Spectr. 2024. PMID: 39656008 Free article.
Intravenous glibenclamide for cerebral oedema after large hemispheric stroke (CHARM): a phase 3, double-blind, placebo-controlled, randomised trial.
Sheth KN, Albers GW, Saver JL, Campbell BCV, Molyneaux BJ, Hinson HE, Cordonnier C, Steiner T, Toyoda K, Wintermark M, Littauer R, Collins J, Lucas N, Nogueira RG, Simard JM, Wald M, Dawson K, Kimberly WT; CHARM Trial investigators. Sheth KN, et al. Lancet Neurol. 2024 Dec;23(12):1205-1213. doi: 10.1016/S1474-4422(24)00425-3. Lancet Neurol. 2024. PMID: 39577921 Clinical Trial.
Optimal antithrombotic therapy in ischemic stroke patients with non-valvular atrial fibrillation and atherothrombosis: study protocol for a randomized controlled trial.
Okazaki S, Yamamoto H, Asakura K, Omae K, Maeda H, Tanaka K, Yamamoto S, Hirano T, Iguchi Y, Sakaguchi M, Koga M, Ihara M, Toyoda K, Noguchi T, Sakai N, Yamagami H. Okazaki S, et al. Among authors: koga m. Front Neurol. 2024 Oct 23;15:1468523. doi: 10.3389/fneur.2024.1468523. eCollection 2024. Front Neurol. 2024. PMID: 39539664 Free PMC article.
1,809 results